[{"id":"326fc09f-923f-42f8-96c2-f5c6e69e46e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03284385","created_at":"2021-01-18T16:13:32.739Z","updated_at":"2024-07-02T16:35:13.144Z","phase":"Phase 2","brief_title":"Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2","source_id_and_acronym":"NCT03284385","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SETD2","pipe":" | ","alterations":" SETD2 mutation","tags":["SETD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SETD2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adavosertib (AZD1775)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/29/2019","start_date":" 01/29/2019","primary_txt":" Primary completion: 08/30/2024","primary_completion_date":" 08/30/2024","study_txt":" Completion: 08/30/2024","study_completion_date":" 08/30/2024","last_update_posted":"2024-03-22"},{"id":"6a7cc96b-1a8d-4c60-a5b9-6a9e7c5f86aa","acronym":"NBIBLI","url":"https://clinicaltrials.gov/study/NCT03748667","created_at":"2021-08-02T20:53:11.763Z","updated_at":"2024-07-02T16:35:36.493Z","phase":"","brief_title":"Accuracy for Predicting Deep Submucosal Invasion","source_id_and_acronym":"NCT03748667 - NBIBLI","lead_sponsor":"Althaia Xarxa Assistencial Universitària de Manresa","biomarkers":" EGFR • HER-2 • TP53 • PIK3CA • PTEN • HRAS • CDKN2A • ARID1A • CTNNB1 • FBXW7 • KMT2C • MUC16 • POLD1 • SETD2 • ARID2 • FAT4 • CSMD1 • DAPK1 • SYNE1 • PCLO • RYR3 • ZFHX4","pipe":"","alterations":" ","tags":["EGFR • HER-2 • TP53 • PIK3CA • PTEN • HRAS • CDKN2A • ARID1A • CTNNB1 • FBXW7 • KMT2C • MUC16 • POLD1 • SETD2 • ARID2 • FAT4 • CSMD1 • DAPK1 • SYNE1 • PCLO • RYR3 • ZFHX4"],"overall_status":"Completed","enrollment":" Enrollment 426","initiation":"Initiation: 12/01/2018","start_date":" 12/01/2018","primary_txt":" Primary completion: 09/28/2022","primary_completion_date":" 09/28/2022","study_txt":" Completion: 10/30/2022","study_completion_date":" 10/30/2022","last_update_posted":"2023-09-21"},{"id":"12441980-737d-4616-9bf1-f93f67db0099","acronym":"","url":"https://clinicaltrials.gov/study/NCT01665703","created_at":"2021-01-18T07:12:01.461Z","updated_at":"2024-07-02T16:36:36.476Z","phase":"","brief_title":"Imaging Correlates of Renal Cell Carcinoma Biological Features","source_id_and_acronym":"NCT01665703","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" PBRM1 • KMT2D • HIF1A • SETD2 • MLL2","pipe":" | ","alterations":" KMT2D mutation • PBRM1 mutation • VHL mutation • HIF1A expression","tags":["PBRM1 • KMT2D • HIF1A • SETD2 • MLL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2D mutation • PBRM1 mutation • VHL mutation • HIF1A expression"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 08/01/2012","start_date":" 08/01/2012","primary_txt":" Primary completion: 11/01/2014","primary_completion_date":" 11/01/2014","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2021-01-07"}]